Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 10:00:05 14/01/2026 pm IST			5-day change	1st Jan Change
558.00 ^CHF	-0.46%		+3.79%	+3.76%

14/01	Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12	Swiss trade surplus at CHF 3.841 bln in November	RE

Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG.

Published on 11/24/2025

S&P Capital IQ

Lonza Group AG

-0.46%

Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG (SWX:LONN) on November 24, 2025. Microsize and Schedio will jointly invest in Mic Mac to further enhance its capabilities and accelerate modernization. The partnership aims to establish an integrated European-American network for advanced particle engineering, combining Microsize?s CDMO expertise with Schedio?s process equipment and containment technologies.

The transaction is subject to customary closing conditions and is expected to close on February 28, 2026.

Latest news about Lonza Group AG

14/01	Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12	Swiss trade surplus at CHF 3.841 bln in November	RE
10/12	The Berkeley Group Holdings plc Appoints Barbara Richmond as Independent Non-Executive Board Director, Effective 1 January 2026	CI
25/11	Morgan Stanley Upgrades Lonza Group to Overweight, Lifts PT	MT
24/11	Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG.	CI
24/11	Microsize, Inc. and Schedio SA signed an agreement to acquire Micro-Macinazione S.A. from Lonza Group AG.	CI
20/11	Swiss trade surplus at CHF 4.32 bln in October	RE
27/25/27	Lonza acquires Redberry	RE
27/25/27	Lonza Group AG signed an agreement to acquire Redberry SAS.	CI
23/25/23	Lonza Group AG, Q3 2025 Earnings Call, Oct 23, 2025
23/25/23	Swiss Market Index Extends Losses; Lonza Group Gains	MT
23/25/23	Lonza is having discussions and investing in the US, CFO says	RE
23/25/23	Lonza Group AG Confirms Sales Guidance for the Second Half 2025	CI
23/25/23	LONZA GROUP : Strong Q3 performance commentary aligns with full-year goals
23/25/23	Singapore Shares End Higher Overlooking Overnight Volatility on Wall Street	MT
23/25/23	Lonza Confirms Full-Year Outlook After Robust Q3 Growth	MT
23/25/23	Lonza Says It Is on Track to Deliver Guidance	DJ
23/25/23	Lonza Group confirms full year 2025 outlook for CDMO and CHI businesses	RE
23/25/23	Lonza confirms outlook as it expects more contracts in coming months	RE
23/25/23	Swiss stocks - Factors to watch on October 23	RE
23/25/23	Switzerland's Lonza Affirms FY25 Outlook	MT
23/25/23	Lonza confirms full-year outlook	RE
23/25/23	Lonza Group Ag Affirms Earnings Guidance for 2025	CI
21/25/21	Swiss trade surplus at CHF 4.073 bln in September	RE
07/25/07	European sovereignty, defense… Oddo BHF presents its "Magnificent Seven"

Chart Lonza Group AG

Duration

Period

LONN: Dynamic Chart

Company Profile

Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (57.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (16.5%). In addition, the group offers nutritional ingredients; - small molecule drug substances (15.3%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.8%).

Employees

19,299

Sector

Biotechnology & Medical Research

Calendar

28/01 - Q4 2025 Earnings Release

More about the company